PharmaLex is proud to announce the first approved application for BioBag® 50/100/200/300 medicinal larvae for Biomonde GmbH – a pharmaceutical company based in Barsbüttel, Germany.
PharmaLex has provided BioMonde with various regulatory activities in relation to the preparation, submission, and coordination of this successful marketing authorization application via the Decentralized Procedure (DCP) in several EU- countries for BioBag®.
BioBag® is the first application via a European procedure for medicinal larvae. BioBag is used for Debridement of documented chronic or badly healing wounds if instrumental/ surgical treatment is not desired
CEO / Geschäftsführer G. Kempson, Biomonde GmbH:
“The professionalism and expertise of the PharmaLex Team, in particular, that of Heike Busse was key to achieving this successful outcome. We are naturally delighted to achieve this landmark European regulatory approval and are grateful for the help and support of our partner. “
About BioMonde GmbH:
BioMonde is a European wound care company specializing in the manufacture and distribution of larval debridement therapy (also known as maggot therapy) products for use in chronic and hard to heal wounds. Our state-of-the-art pharmaceutical production units in the UK and Germany, together with our commitment to research, development and education, make BioMonde the first choice in wound debridement.